Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M505790200 on November 8, 2005

J. Biol. Chem., Vol. 281, Issue 2, 775-781, January 13, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/2/775    most recent
M505790200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neidlinger, N. A.
Right arrow Articles by Kuypers, F. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neidlinger, N. A.
Right arrow Articles by Kuypers, F. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Hydrolysis of Phosphatidylserine-exposing Red Blood Cells by Secretory Phospholipase A2 Generates Lysophosphatidic Acid and Results in Vascular Dysfunction*

Nikole A. Neidlinger{ddagger}§1, Sandra K. Larkin§, Amrita Bhagat§, Gregory P. Victorino{ddagger}, and Frans A. Kuypers§

From the {ddagger}Department of Surgery, University of California, San Francisco-East Bay, Oakland, California 94602 and §Children's Hospital Oakland Research Institute, Oakland, California 94609

Received for publication, May 26, 2005 , and in revised form, October 19, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Secretory phospholipase A2 (sPLA2) type IIa, elevated in inflammation, breaks down membrane phospholipids and generates arachidonic acid. We hypothesized that sPLA2 will hydrolyze red blood cells that expose phosphatidylserine (PS) and generate lysophosphatidic acid (LPA) from phosphatidic acid that is elevated in PS-exposing red blood cells. In turn, LPA, a powerful lipid mediator, could affect vascular endothelial cell function. Although normal red blood cells were not affected by sPLA2, at levels of sPLA2 observed under inflammatory conditions (100 ng/ml) PS-exposing red blood cells hemolyzed and generated LPA (1.2 nM/108 RBC). When endothelial cell monolayers were incubated in vitro with LPA, a loss of confluence was noted. Moreover, a dose-dependent increase in hydraulic conductivity was identified in rat mesenteric venules in vivo with 5 µM LPA, and the combination of PS-exposing red blood cells with PLA2 caused a similar increase in permeability. In the presence of N-palmitoyl L-serine phosphoric acid, a competitive inhibitor for the endothelial LPA receptor, loss of confluence in vitro and the hydraulic permeability caused by 5 µM LPA in vivo were abolished. The present study demonstrates that increased sPLA2 activity in inflammation in the presence of cells that have lost their membrane phospholipid asymmetry can lead to LPA-mediated endothelial dysfunction and loss of vascular integrity.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Secretory phospholipase A2(sPLA2)2 type IIa is a low molecular weight, ubiquitous enzyme that is elevated in inflammation. The enzyme generates arachidonic acid from phospholipids for the generation of thromboxanes and leukotrienes and, as such, acts as an essential mediator in the inflammatory pathways (1). The specific membranes targeted by the enzyme for the generation of arachidonic acid during inflammation have not been clearly defined. Secretory PLA2 has a strong preference for phospholipids that are negatively charged at physiologic pH: phosphatidylserine (PS) and phosphatidylethanolamine (PE) (2). In normal mammalian cells, these phospholipids are mainly (PE) or exclusively (PS) confined to the inner layer of the plasma membrane (1–3). Loss of this asymmetric distribution and exposure of PS on the external surface generates a thrombogenic surface and signals macrophages to remove cells by phagocytosis (1–5). Although normal mammalian cells do not seem to act as targets for sPLA2, loss of phospholipid asymmetry in plasma membranes and the exposure of PS have been shown to render them vulnerable to phospholipid hydrolysis (1). In addition, it has been well established that bacterial membranes are excellent substrates for this enzyme (6). Together, membranes with altered phospholipid packing are potential targets for sPLA2 type IIa.

We have previously shown that sPLA2 is elevated after injury, predicts hypoxemia, and is related to multiorgan failure (7, 8). In addition, elevated levels of sPLA2 predict the onset of the acute chest syndrome in sickle cell disease (9–11), the severe lung damage that is a major cause of death in these patients. Although tissue damage under these conditions is clearly related to sPLA2 levels, the cellular targets and mechanisms by which sPLA2 incites injury remain elusive.

We have reported that under conditions that lead to PS exposure in red blood cells, an intracellular phospholipase D is activated that generates phosphatidic acid (PA) by hydrolysis of phosphatidylcholine (12). We hypothesized that the interaction between sPLA2 and PS-exposing red blood cells could result in lysophosphatidic acid (LPA) generation from PA present at elevated levels in these cells. LPA is an important lipid mediator with a number of physiologic effects, including platelet aggregation, smooth muscle contraction, vasoactive changes, cytoskeletal reorganization, and stimulation of cell proliferation (2, 13–16) involving G-protein-coupled receptors that are present on various cell types (16, 17). Concentration of LPA in human serum has been measured in ranges from 0.6–10 µM. Although healthy individuals show LPA levels consistently below 1 µM, higher levels of LPA are observed in diseases such as ovarian cancer and sickle cell disease (18–22). Sources of LPA have recently been investigated and reviewed (1, 2, 18, 23–25). It was indicated that LPA is produced in platelets when they are activated by thrombin (26); however, the amount of LPA produced in this manner only accounts for a small part of the LPA in serum (25). Multiple phospholipases are thought to be involved in LPA production, including sPLA2, phosphatidylserine-specific phospholipase A1, and lechitin-cholesterol acyltransferase (23, 24). It is also suggested that lysophosphatidylcholine generated from PLA2 can be hydrolyzed by lysophospholipase D into LPA (23, 24).

We hypothesized that PA that is formed in PS-exposing cells could convert to LPA by sPLA2 activity. If so, this could affect endothelial cell monolayer and vascular integrity. To test this hypothesis, we determined whether PS-exposing red blood cells are susceptible to sPLA2 and whether sPLA2 activity leads to the formation of LPA. We identified the impact of PS-exposing red blood cells and LPA on endothelial cell monolayer integrity in vitro and examined the effect of LPA on venular hydraulic conductivity in vivo.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
All chemicals were the highest grade available and were purchased from Sigma unless otherwise specified.

PS-exposing Red Blood Cells and sPLA2—With approval of the Institutional Review Board, human venous blood from healthy consenting volunteers was drawn in EDTA anticoagulant tubes. Blood was spun at 1000 x g, the plasma and buffy coat were removed, and the erythrocytes were washed three times in Hepes-buffered saline. Subsequently, a portion of red blood cells was incubated with 10 µM oligomycin A and 100 µM CaCl2 in Hepes-buffered saline for 3 min at 37 °C to initiate phospholipid scrambling. Calcium Ionophore A23187 [GenBank] was added to a final concentration of 4 µM, and the cells were further incubated for 10 min at 37 °C. Subsequently, 2 mM EDTA was added.

To confirm that the membrane exposed PS, cells were incubated with fluorescently labeled Annexin V and analyzed by flow cytometry (FACS Calibur; BD Biosciences) as described before (27). PS-exposing red blood cells at 109 cells/ml or an equal volume of control erythrocytes were incubated with 100 ng/ml of type IIa human sPLA2 (Cayman Chemical, Ann Arbor MI) for 1 h at 37° C in Hepes-buffered saline with 2mM calcium.

Hemolysis was measured by determination of hemoglobin in the supernatant of the red blood cell suspension after centrifugation at 4000 x g. The absorbance at 410 nm in the supernatant was compared with the absorbance of a hemolyzed aliquot of the same red blood cell suspension in water in a Spectra Max 340 spectrophotometer (Molecular Devices, Sunnyvale CA). In addition, red cell integrity was determined by a simple cell count of the total number of intact cells in the red cell suspension by flow cytometry. PS exposure after sPLA2 treatment was measured by flow cytometry as described above.

LPA Assay—To analyze the presence of LPA in the red cell suspensions, lipids were extracted according to Rose and Oaklander (28) and LPA in the lipid extracts were measured by radioenzymatic assay as described previously (21) with few modifications. In this assay lysophosphatidic acid acyl transferase (LPAAT) is used to reacylate LPA to 14C-labeled PA with 14C-labeled palmitoyl-CoA. LPAAT was produced in plasmid-transformed Escherichia coli, a generous gift from Jean Sebastian Saulnier-Blanche (Paris, France). E. coli were grown under routine conditions in Luria-Bertani medium and disrupted with an M-110S air-powered microfluidizer pump (Microfluidics International Corp., Newton MA). The resulting membrane preparations were recovered by centrifugation of the supernatant for 90 min at 100,000 x g, and the protein concentration was determined using the Bradford protein assay (29) and Coomassie reagent (Pierce Biotechnology). Standard solutions of LPA (Na+ salt of 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphate; Avanti%20Polar%20Lipids">Avanti Polar Lipids, Alabaster, AL) were prepared in chloroform/methanol (2:1, v:v).

LPA concentrations in the standard solutions were determined by phosphate analysis (30). Both standard LPA solutions and cellular lipid extracts were incubated in 200 µl of reaction medium (7.4 µM [14C]palmitoyl-CoA) (specific radioactivity 60µCi/µmol; PerkinElmer Life Sciences), 20 mM Tris (pH 7.4), 0.25 mg/ml lysophosphatidic acid acyl transferase, 20 µM sodium orthovanadate, and 136 µlofH20 containing 1.5 mg/ml Tween 20) for 20 min. After adding 400 µl of CHCl3-methanol-12 M HCl (40:40:0.26, v:v) to stop the reaction, the lower CHCl3 phase was evaporated under nitrogen and resuspended in CHCl3.

Subsequently, lipids were extracted according to Bligh and Dyer (31) and separated by thin layer chromatography (TLC) on Analtech silica gel plates in an acidic TLC solvent (100 ml of CHCl3, 50 ml of MeOH,16 ml of acetic acid, 5 ml of 0.9% NaCl) to separate [14C]PA from [14C]palmitic acid and [14C]palmitoyl-CoA. Quantification of radioactivity in the separated lipid spots on TLC utilized a Storm 840 Phosphor-Imager (Amersham Biosciences) with digital image analysis using ImageQuant software (Molecular Dynamics). It was determined that this method rendered virtually identical results as compared with scintillation counting after scraping of the TLC plate (r2 = 0.98). We tested the required incubation time for PA formation from LPA and found that under our conditions PA formation from LPA was complete after 20 min of incubation.

Endothelial Cell Cultures—Human umbilical vein endothelial cells (HUVEC) were harvested from umbilical cords obtained from Alta Bates Hospital according to Institutional Review Board-approved protocols. HUVEC were grown on 2% gelatin in endothelial growth medium (Biowhittaker, Walkersville MD) and were maintained at 37 °C in 5% CO2 in 24-well plates. Confluence and morphology of the mono-layers were determined by light microscopy.

After 3–6 days of culture, each well was aspirated and washed with endothelial growth medium to remove any detached cells. LPA or lysophosphatidylcholine (LPC) standards were prepared in chloroform/methanol (2:1, v:v). Aliquots of these lysophospholipids were evaporated under a stream of nitrogen and resuspended in endothelial growth medium. HUVEC monolayers were exposed to endothelial growth medium containing various concentrations of either LPA or LPC for 90 min at 37 °C. Following exposure to LPA or LPC, detached HUVEC in the supernatant were identified and counted by flow cytometry. Mouse anti-vascular cell adhesion molecule and phycoerythrin-labeled goat anti-mouse IgG secondary antibody were used to identify intact HUVEC. To quantify the percentage of HUVEC detachment in the experimental groups, complete detachment of HUVEC was induced by incubation with detaching buffer (10 mM NaPO4, 150 mM NaCl, 5 mM NaHCO3, 10 mM EDTA, 0.1% bovine serum albumin, and 1 mM phenylmethylsulfonyl fluoride) (32).

In Vivo Hydraulic Permeability—All studies were approved and complied with institutional animal research protocols. The methods and preparations have been described in detail previously (33) and are discussed in brief here. Adult female Sprague-Dawley rats (Hilltop Lab Animals Inc., Scottsdale, PA) were anesthetized with sodium pentobarbital (60 mg/kg). The small bowel mesentery was exposed and positioned over a quartz pillar for examination on an inverted microscope (Diaphot; Nikon, Melville, NY). Red blood cell markers were obtained from adult female Golden Syrian hamsters (Harlan, Indianapolis, IN). Perfusates consisted of Ringer's solution (135 mM NaCl, 4.6 mM KCl, 2.0 mM CaCl2, 2.46 mM MgSO4, 5.0 mM NaHCO3, 5.5 mM dextrose, 9.03 mM Hepes salt, 11.04 mM Hepes acid), 1% bovine serum albumin, red blood cell markers, and test mediators LPA and the LPA receptor antagonist, N-palmitoyl L-serine phosphoric acid (L-NASPA; Biomol Research, Plymouth Meeting, PA).

Single vessel hydraulic permeability (Lp) was determined using the modified Landis microcannulation technique (34). The assumptions and limitations of this model have been previously described (33). Initial cell velocity (dl/dt) was obtained by recording marker cell position as a function of time. Transmural water flux per unit area (Jv/S) was calculated by the equation Jv/S = (dl/dt)(r/2l), where r is the vessel radius and l is the initial distance between the marker red blood cell and the placement of the vessel occluder. Determination of hydraulic permeability (Lp) was based on the equation of fluid filtration: Lp = (Jv/S)(1/Pc). In this equation, Pc represents hydrostatic pressure and Lp was calculated from the slope of the regression Jv/S on Pc, derived from three different occlusion measurements at fixed perfusion pressures. Control studies documenting the stability of the model over time and after repeat cannulations have been previously reported (35).


Figure 1
View larger version (9K):
[in this window]
[in a new window]
  		FIGURE 1.
Dose-dependent effect of sPLA2 on hemolysis of PS-exposing and intact human erythrocytes. Normal and PS-exposing red blood cells were incubated with concentrations of sPLA2 ranging from 0–500 ng/ml for 1 h at 37° C. Hemolysis was measured by the amount of cell-free hemoglobin in the cell lysates compared with an equal volume of hypotonically lysed RBC. Normal red blood cells (white bars) were unaffected by sPLA2 regardless of its concentration. PS-exposing red blood cells (gray bars) were hemolyzed in a dose-dependent manner. Values are the means ± S.E. of six independent experiments (p <0.01).

 
In each experiment, venules were cannulated and perfused with 1% bovine serum albumin/Ringer's solution for 10 min and baseline Lp was measured. To evaluate the effect of PLA2 and PS-exposing RBC on hydraulic conductivity, we measured the hydraulic permeability induced by 2 x 108 PS-exposing RBC in the presence or absence of 100 ng of pancreatic PLA2 in 1 ml of 1% bovine serum albumin/Ringer's perfusate. In vitro experiments indicated that the combination of this amount of PS-exposing RBC and PLA2 could produce 3 µM LPA, a concentration comparable with the conditions in which exogenously LPA was added. For the in vivo study we used porcine pancreatic PLA2 rather than human secretory PLA2 because it is more readily available to be used in the concentrations needed. Moreover, our in vitro studies show that pancreatic PLA2 had similar effects on PS-exposing RBC as sPLA2. To evaluate the effect of LPA, venules were perfused with clinically relevant concentrations of 1 and 5 µM LPA (16). Measurements of Lp were taken at 2- and then at 5-min intervals to 20 min with continuous LPA perfusion (n = 5). To examine the effect of the inhibitor L-NASPA on Lp, venules were first perfused with L-NASPA (20 µM) and Lp measured at 5 and 15 min. Next, venules were perfused simultaneously with LPA (5 µM) and L-NASPA (20 µM) and Lp measured at 2 min and then every 5 min to a total of 20 min (n = 6).

Statistics—Comparisons of means were made with Student's t-test. Group means of sequential measurements in permeability measurements were analyzed with repeated measures of analysis of variance with post hoc analysis. Statistical significance was set at an {alpha} error of 5%. All values for Lp are represented as mean ± S.E. x 10–7 cm·s–1·cmH2O–1.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Hydrolysis of Normal and PS-exposing Red Blood Cells by sPLA2—To show that PS-exposing red blood cells would be a target for sPLA2 we incubated both normal and PS-exposing erythrocytes with different concentrations of purified sPLA2. Although sPLA2 was virtually unable to act on normal erythrocytes, it hemolyzed erythrocytes that exposed PS in a dose-dependent manner (Fig. 1). The concentrations of sPLA2 that hydrolyzed PS-exposing red blood cells are similar to sPLA2 concentrations reported in sera of trauma and septic patients (7, 8, 10). Flow cytometric analysis confirmed the loss of PS-exposing cells after sPLA2 incubation. Fig. 2 depicts a typical flow cytometry histogram of PS-exposing cells before and after incubation with varying doses of sPLA2. As the dose of sPLA2 increases, the remaining erythrocyte population after 1 h decreases. In addition, Annexin V fluorescence decreases with increasing sPLA2 concentration, suggesting that the remaining cells after sPLA2 exposure do not expose PS. As shown in Fig. 3, hemolysis of PS-exposing red blood cells increased with time when these cells were exposed to 100 ng/ml of sPLA2. Similarly, as hemolysis increases, the percentage of PS-exposing cells remaining decreases as measured by flow cytometry. This inverse relationship confirms that sPLA2 targets red blood cells that expose PS. Similar results were found when PS-exposing RBC were incubated with porcine pancreatic PLA2 (not shown).


Figure 2
View larger version (10K):
[in this window]
[in a new window]
  		FIGURE 2.
sPLA2 targets PS-exposing erythrocytes. PS-exposing red blood cells bind fluorescently labeled Annexin V (dashed outline). After 1 h with sPLA2 at 2–500 ng/ml, flow cytometry was used to identify the number (counts) and membrane configuration (fluorescence of Alexa Annexin) of the remaining cells as described under "Experimental Procedures." Histograms of cell populations exposed to 2 ng/ml (solid outline), 50 ng/ml (solid gray), and 500 ng/ml (solid black) of sPLA2 are depicted. As doses of sPLA2 increase, the number of cells remaining decreases and the remaining cells are less likely to bind Alexa Annexin. After 500 ng/ml of sPLA2 (black histogram), virtually no intact RBC remain.

 
LPA Formation—Conditions that lead to PS exposure are associated with activation of phospholipase D (12). When cells are incubated under conditions that increase their intracellular calcium, phosphatidylcholine is hydrolyzed and PA is formed (12). We hypothesized that if PS-exposing red blood cells are hydrolyzed by sPLA2, this could result in LPA formation by hydrolysis of PA. We measured LPA formation in erythrocytes by the formation of 14C-labeled PA after incubation of the red blood cell lipid extract with radiolabeled palmitoyl-CoA and LPA-acyltransferase as described above. Virtually no increase in LPA formation was found in PS-exposing red blood cells as compared with normal red blood cells in the absence of sPLA2 (3.5 ± 1.2 versus 3.2 ± 1.5 nmol/1010 cells LPA, mean ± S.E., p = 0.9). Normal erythrocytes that were exposed to 100 ng/ml of sPLA2 showed no significant change in LPA concentration (5.8 ± 1.8 nmol/1010 cells LPA, p = 0.3). In contrast, a dramatic increase in LPA formation was observed when PS-exposing cells were exposed to 100 ng/ml of sPLA2 (122.4 ± 21.8 nmol/1010 cells LPA, p <0.001) (Fig. 4). When PS-exposing red blood cells were incubated with 100 ng/ml of sPLA2 in the absence of calcium in the buffer, no LPA was generated, indicating that sPLA2 needs to be catalytically active. Similar results were found when PS-exposing RBC were incubated with porcine pancreatic PLA2 (not shown).

Effects of LPA on Endothelial Monolayers in Vitro and Vascular Integrity in Vivo—LPA was reported to be implicated in the inflammatory response of endothelial cells (17) and endothelial cell retraction and monolayer permeability (5). To correlate LPA derived from PS-exposing cells, we exposed confluent HUVEC monolayers to LPA and monitored morphological changes by microscopy. Endothelial monolayers grown to confluency show the characteristic cobblestone pattern (Fig. 5A1). When these monolayers were exposed to LPA a loss of monolayer confluence was observed, consistent with cellular detachment from the matrix (Fig. 5A2). To quantify this apparent detachment we analyzed the supernatant by flow cytometry (Fig. 5B). The number of cells identified as endothelial cells using mouse anti-vascular cell adhesion molecule and phycoerythrin-labeled goat anti-mouse IgG increased in the supernatant as the result of exposure of the cells to LPA. We calculated the percentage of cells detached under different conditions by comparing the number of endothelial cells in the supernatant before and after complete cellular detachment of the monolayer induced by EDTA in detaching buffer as described under "Experimental Procedures." Endothelial cell detachment caused by incubation with 20 µM LPA at 90 min (37 ± 2%) was significantly higher as compared with control incubations (0 ± 5% p <0.01). Comparison of the effect of LPA, which has a specific receptor on endothelial cells, with LPC showed that LPC at the same dose (20 µM) caused significantly less detachment than LPA (16 ± 9%, p <0.01). This suggested a specific effect of LPA on endothelial monolayers rather than a general effect of lysophospholipids. The observed effect on the endothelial monolayers was concentration dependent. Incubation with 10 µM LPA resulted in a lower, but still significant, increased detachment as compared with control (23 ± 3%, p <0.01). Together these results suggest that LPA formed by the interaction of PS-exposing cells and PLA2 can result in a loss of endothelial integrity under inflammatory conditions, possibly resulting in increased vascular permeability.


Figure 3
View larger version (12K):
[in this window]
[in a new window]
  		FIGURE 3.
PS-exposing red blood cells are targeted and lysed by sPLA2 in a time-dependent manner. Cells induced to expose PS were incubated with 100 ng/ml of sPLA2. At 20-min intervals, a sample was removed and hemolysis and PS exposure measured as described under "Experimental Procedures." As time increases, hemolysis increases (solid line) and PS exposure of the remaining cells decreases (dashed line). Values are the means ± S.E. of five independent experiments.

 


Figure 4
View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 4.
The interaction of PS-exposing red blood cells and sPLA2 causes LPA formation. A, intact and PS-exposing erythrocytes were incubated for 1 h at 37° C in the absence (lanes 1–2) or presence (lanes 3–4) of 100 ng/ml of sPLA2. To quantify LPA, lipids were extracted and LPA reacylated with lysophosphatidic acid acyl transferase in the presence of [14C]palmitoyl-CoA to form [14C]PA. Products were separated with TLC. [14C]PA formation is an indirect measure of LPA in the original sample. LPA was quantified as described under "Experimental Procedures," and results are shown in panel B. Normal red blood cells (C) and PS-exposing red blood cells (PS+) were incubated in the presence (+) or absence (–) of 100 ng/ml of sPLA2. Values are means ± S.E. of eight independent experiments (p <0.01).

 


Figure 5
View larger version (58K):
[in this window]
[in a new window]
  		FIGURE 5.
LPA caused endothelial detachment in vitro. Confluent HUVEC monolayers (panel A1) were incubated with 0, 10, and 20 µM LPA as described under "Experimental Procedures." Under the light microscope, LPA-treated HUVEC showed retraction, loss of cobblestone appearance, and intercellular gaps with exposed matrix (panel A2). B, quantification with flow cytometry confirmed this dose-dependent detachment after LPA exposure. Results shown are means ± S.D. of three independent experiments (p <0.01 for both 10 and 20 µM compared with control).

 
To test this, we exposed single venules to PS-exposing RBC in the presence or absence of PLA2 and to clinically relevant doses of LPA and measured hydraulic conductivity (Lp) as described under "Experimental Procedures." Results are depicted in Fig. 6. The presence of PS-exposing RBC slightly increased Lp (1.27 ± 0.05) as compared with baseline (1.00 ± 0.08 x 10–7 cm·s–1·cmH2O–1). Phospholipase A2 in the absence of PS-exposing RBC had only a modest effect on Lp (1.61 ± 0.25 x 10–7 cm·s–1·cmH2O–1) compared with baseline (1.00 ± 0.08 x 10–7 cm·s–1·cmH2O–1). However, the combination of PS-exposing RBC and a clinically relevant dose (100 ng/ml) of PLA2 caused >3-fold increase in Lp, with maximal effect at 10 min perfusion (3.27 ± 0.26 x 10–7 cm·s–1·cmH2O–1). We determined that this amount of PS-exposing RBC in the presence of PLA2 would generate ~3 µM LPA. To show that the increase in hydraulic conductivity induced by the action of PLA2 on PS-exposing RBC would be comparable with that seen with similar, clinically relevant doses of LPA, we measured hydraulic conductivity (Lp) after exposing single mesenteric venules to 1–5 µM LPA. Maximal Lp was noted after 5 min perfusion with LPA and was dose dependent. Maximal Lp with 1 and 5 µM LPA were 1.47 ± 0.01 and 3.16 ± 0.17 x 10–7 cm·s–1·cmH2O–1, respectively. Both were significantly increased from the baseline Lp of 1.00 ± 0.08 x 10–7 cm·s–1·cmH2O–1 (p <0.001). To further show the specificity of LPA to induce an increase in hydraulic conductivity, we tested the effect of an inhibitor reported to affect the interaction of LPA with its receptor on Xenopus laevis oocytes (36, 37) and human platelets (38). Although the inhibitory effect of this compound on endothelial cells was not reported, we hypothesized a similar interference on the endothelial activation of LPA. The LPA receptor antagonist N-palmitoyl L-serine phosphoric acid (L-NASPA) had no effect on Lp when infused for 15 min at 20 µM. The maximal Lp of 1.07 ± 0.04 x 10–7 cm·s–1·cmH2O–1 seen during infusion of L-NASPA was not significantly different from the baseline Lp (p = 0.83). Fig. 7 shows the effect on Lp in time by infusion of 5 µM LPA in the absence or presence of 20 µM L-NASPA. The antagonist was able to completely inhibit the hydraulic conductivity caused by 5 µM LPA (maximum Lp = 3.16 ± 0.17 x 10–7 cm·s–1·cmH2O–1, 5 min perfusion). In the presence of the antagonist, the Lp seen at 5 min perfusion with 5 µM LPA is no different from baseline Lp (1.14 ± 0.04 versus 1.06 ± 0.03 x 10–7 cm·s–1·cmH2O–1, p = 0.1).


Figure 6
View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 6.
PS-exposing RBC and PLA2 caused increased venular hydraulic conductivity. A, post-capillary mesenteric venules were isolated, cannulated, and perfused with PS-exposing RBC (dotted line, open circles) and 100 ng/ml of PLA2 (dashed line, open triangles). Hydraulic conductivity (Lp) seen with a combination of PS-exposing RBC and 100 ng/ml of PLA2 (solid line) peaked at 3-fold over baseline. Values shown are means ± S.E. and include five vessels in three animals (p <0.01 at 2, 5, 10, and 15 min). B, LPA caused an increase in post-capillary hydraulic conductivity in vivo. Single post-capillary mesenteric venules were isolated, cannulated, and perfused with 0, 1, and 5 µM LPA using the modified Landis microcannulation technique as described under "Experimental Procedures." LPA caused an increase in hydraulic permeability (Lp) versus baseline. Results are shown as means ± S.E. of five vessels in three animals (p <0.01 for 1 and 5 µM compared with control).

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Secretory PLA2 has a strong preference for anionic phospholipids, and it has been suggested that the action of sPLA2 requires exposure of the aminophospholioids, phosphatidylethanolamine and PS, on the external leaflet of the membrane (1, 2). It was shown that microvesicles derived from cells with a loss of membrane asymmetry provided a preferential substrate for sPLA2, and LPA formation from PA hydrolysis by sPLA2 was identified in a time- and dose-dependent manner (1). We argued that in inflammatory states with increased concentrations of circulating sPLA2, phospholipids of PS-exposing cells could potentially be hydrolyzed when these cells are not removed in a timely manner by macrophage phagocytosis. If this were indeed the case it would lead to increased levels of LPA and potentially affect the integrity of vascular endothelium. We have shown that indeed PS-exposing red blood cells are a target for sPLA2. Normal RBC do not generate LPA in the presence of sPLA2, and in the absence of calcium, sPLA2 will not generate LPA from PS-exposing cells. Taken together, these data support the need for a catalytically active sPLA2.


Figure 7
View larger version (7K):
[in this window]
[in a new window]
  		FIGURE 7.
LPA receptor blockade with L-NASPA inhibited hydraulic conductivity seen with LPA exposure to baseline levels. Post-capillary rat mesenteric venules were isolated, cannulated, and perfused with LPA (5 µM) and the specific LPA receptor blocker, L-NASPA (20 µM). Hydraulic conductivity (Lp) with continuous LPA perfusion, which peaked at >3-fold over baseline, is shown in the solid line. When the same concentration of LPA was infused simultaneously with L-NASPA, the hydraulic permeability was reduced to baseline levels (dashed line). Values shown are means ± S.E. and include six vessels in three animals (p <0.01 at 2, 5, 10, 15 min).

 
Cells that expose PS are degraded by sPLA2, and lysophospholipids, including LPA, are formed. The relatively high concentration of LPA generated by the action of sPLA2 on PS-exposing red blood cells is likely the result of an increase in the concentration of PA generated in these cells by the activation of a phospholipase D that hydrolyzes phosphatidylcholine under conditions that lead to PS exposure (12). Previously, both phospholipase D and sPLA2 have been implicated in the increased levels of LPA released by ovarian cancer cells (18). Our data provide evidence that supports a mechanism by which PS-exposing cells not removed by macrophages may be a source for LPA under inflammatory conditions. This in turn may lead to pathology. The asymmetric distribution of phospholipids across the plasma membrane bilayer is well maintained in all mammalian cells, with PS present exclusively in the inner monolayer. The loss of asymmetry and exposure of PS is an early step in programmed cell death (39, 40), and apoptotic or necrotic cells that expose PS are removed by macrophages that recognize PS in plasma membranes (2, 3).

Secretory PLA2 has been implicated in acute respiratory distress syndrome, a clinical condition that carries up to a 50% mortality rate in affected patients, and in the histologically and clinically similar acute chest syndrome of sickle cell disease (9, 11, 41–43). While high concentrations of sPLA2 are observed in acute chest syndrome patients, we have found low numbers of PS-exposing red blood cells in the circulation of these patients. In contrast, a subpopulation of PS-exposing erythrocytes is found in sickle cell disease patients who do not exhibit acute chest syndrome (27, 44). Data in these reports would explain such a finding. PS-exposing red blood cells present in the circulation of acute chest syndrome patients would rapidly be removed by the action of sPLA2. One hallmark of acute respiratory distress syndrome is increase in pulmonary endothelial permeability, such that the gas exchange surface in the lung is dysfunctional due to edema and inflammatory influx (45, 46). The products of sPLA2, non-esterified fatty acids and lysophospholipids, have detergent-like capacities and have the potential to disrupt the endothelial monolayer (47). Infusion of free fatty acid is a well established model for acute respiratory distress syndrome (41, 48–50). Our studies have shown that LPA will disrupt a confluent endothelial monolayer in vitro, possibly due to the presence of a specific LPA receptor on endothelial cells. LPA effectively leads to retraction of endothelial cells. Other studies have reported that activation of the LPA receptor in fibroblasts drives contraction of the actomyosin-based cytoskeleton, causing cellular retraction and cell rounding (15), and HUVEC exposed to LPA cause loss of cobblestone appearance, cell rounding, stress fiber formation, and increase in intercellular gaps similar to our observations (52).

LPA-induced endothelial permeability in HUVEC was reported to be mediated by Rho A and Rho kinase and related to an increase in myosin light chain phosphorylation and an increase in F-actin filaments (51). The appearance of intact endothelial cells that detach from the monolayer after LPA exposure suggests that cells retract and then detach, resulting in gaps in the monolayer. In addition to endothelial dysfunction in vitro, we found that LPA causes significant fluid leak in vivo. Although neither PLA2 alone nor PS-exposing RBC by themselves will lead to appreciable changes in hydraulic conductivity, the combination of the two will lead to increased permeability similar to exogenously added LPA.

Hydraulic permeability in vivo was identified at lower doses than cellular detachment in vitro, and the increase in permeability was, at least in part, reversible. This suggests that upon LPA exposure, endothelial cells first reversibly retract, resulting in fluid leak. At higher LPA concentrations, cells detach from the subcellular matrix.

Inhibiting the interaction of LPA with its receptor can counteract this chain of events. L-NASPA has previously been identified as an antagonist of LPA-induced platelet aggregation (38) and LPA-induced chloride conductance in X. laevis oocytes (19, 37). In human breast cancer cells, L-NASPA had LPA agonist characteristics (53). Observed differences in the antagonistic properties of L-NASPA have led to the discovery of more specific LPA receptor antagonists and LPA receptor subtypes. Three G-protein-coupled receptors for LPA have been cloned (LPA1, LPA2, And LPA3), and specific antagonists have recently been identified for these subtypes (54). Our data provide evidence that the response of endothelial cells to LPA in the rat vasculature tested is receptor mediated. L-NASPA effectively inhibits LPA-induced hydraulic conductivity, confirming the role of LPA as an important mediator in microvascular permeability. Previous reports indicate that activation of the LPA receptor inhibits adenyl cyclase and decreases cyclic AMP levels (15, 55), which may (56) or may not (51) lead to increase in hydraulic conductivity. Our data do not provide evidence for such mechanisms or specific receptors in the rat endothelium involved.

The present study has shown a possible mechanism of sPLA2-induced tissue injury in inflammation. Cells that expose PS are vulnerable to sPLA2. If this material is not properly recognized and removed by macrophages, sPLA2-induced breakdown can have important consequences due to the release of bioactive intracellular mediators into the circulation. One such mediator generated by sPLA2 from PS-exposing cells is LPA, which in turn leads to endothelial dysfunction and vascular leak. The present investigation has outlined a novel role for antagonists of the endothelial LPA receptor pathway as therapeutics to counteract vascular leak.


   FOOTNOTES
 
* This work was supported in part by National Institutes of Health Grants HL66355 and HL070583 (to F. A. K.) and an American College of Surgeons faculty research grant (to G. .P. V.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

1 To whom correspondence should be addressed: Rm. 1114, 5700 Martin Luther King, Jr. Way, Oakland, CA 94609-1673. Tel.: 510-450-7621; Fax: 510-450-7910; E-mail: NeidlingerN{at}surgery.ucsf.edu.

2 The abbreviations used are: sPLA2, secretory phospholipase A2 type IIa; PS, phosphatidylserine; LPA, lysophosphatidic acid; PA, phosphatidic acid; LPC, lysophosphatidyl-choline; HUVEC, human umbilical vein endothelial cells; Lp, hydraulic permeability; L-NASPA, N-palmitoyl L-serine phosphoric acid; RBC, red blood cell. Back


   ACKNOWLEDGMENTS
 
We thank Brian Curran for skillful technical assistance with in vivo rat studies.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Fourcade, O., Simon, M. F., Viode, C., Rugani, N., Leballe, F., Ragab, A., Fournie, B., Sarda, L., and Chap, H. (1995) Cell 80, 919–927[CrossRef][Medline] [Order article via Infotrieve]
  2. le Balle, F., Simon, M. F., Meijer, S., Fourcade, O., and Chap, H. (1999) Adv. Enzyme Regul. 39, 275–284[CrossRef][Medline] [Order article via Infotrieve]
  3. Zwaal, R. F., and Schroit, A. J. (1997) Blood 89, 1121–1132[Free Full Text]
  4. Manodori, A. B., Barabino, G. A., Lubin, B. H., and Kuypers, F. A. (2000) Blood 95, 1293–1300[Abstract/Free Full Text]
  5. van Nieuw Amerongen, G. P., Vermeer, M. A., and van Hinsbergh, V. W. (2000) Arterioscler. Thromb. Vasc. Biol. 20, E127-E133
  6. Wright, G. W., Ooi, C. E., Weiss, J., and Elsbach, P. (1990) J. Biol. Chem. 265, 6675–6681[Abstract/Free Full Text]
  7. Neidlinger, N. A., Hirvela, E. R., Skinner, R. A., Larkin, S. K., Harken, A. H., and Kuypers, F. A. (2005) J. Am. Coll. Surg. 200, 173–178[CrossRef][Medline] [Order article via Infotrieve]
  8. Partrick, D. A., Moore, E. E., Silliman, C. C., Barnett, C. C., and Kuypers, F. A. (2001) Crit. Care Med. 29, 989–993[CrossRef][Medline] [Order article via Infotrieve]
  9. Styles, L. A., Aarsman, A. J., Vichinsky, E. P., and Kuypers, F. A. (2000) Blood 96, 3276–3278[Abstract/Free Full Text]
  10. Styles, L. A., Schalkwijk, C. G., Aarsman, A. J., Vichinsky, E. P., Lubin, B. H., and Kuypers, F. A. (1996) Blood 87, 2573–2578[Abstract/Free Full Text]
  11. Kuypers, F. A., and Styles, L. A. (2004) Cell Mol. Biol. (Noisy-Le-Grand) 50, 87–94[Medline] [Order article via Infotrieve]
  12. Butikofer, P., Yee, M. C., Schott, M. A., Lubin, B. H., and Kuypers, F. A. (1993) Eur. J. Biochem. 213, 367–375[Medline] [Order article via Infotrieve]
  13. Moolenaar, W. H. (1994) Trends Cell Biol. 4, 213–219[CrossRef][Medline] [Order article via Infotrieve]
  14. Moolenaar, W. H. (1995) J. Biol. Chem. 270, 12949–12952[Free Full Text]
  15. Moolenaar, W. H., Kranenburg, O., Postma, F. R., and Zondag, G. C. (1997) Curr. Opin. Cell Biol. 9, 168–173[CrossRef][Medline] [Order article via Infotrieve]
  16. Goetzl, E. J., and An, S. (1998) FASEB J. 12, 1589–1598[Abstract/Free Full Text]
  17. Graler, M. H., and Goetzl, E. J. (2002) Biochim. Biophys. Acta 1582, 168–174[Medline] [Order article via Infotrieve]
  18. Eder, A. M., Sasagawa, T., Mao, M., Aoki, J., and Mills, G. B. (2000) Clin. Cancer Res. 6, 2482–2491[Abstract/Free Full Text]
  19. Baker, D. L., Morrison, P., Miller, B., Riely, C. A., Tolley, B., Westermann, A. M., Bonfrer, J. M., Bais, E., Moolenaar, W. H., and Tigyi, G. (2002) J. Am. Med. Assoc. 287, 3081–3082[Free Full Text]
  20. Xu, Y., Shen, Z., Wiper, D. W., Wu, M., Morton, R. E., Elson, P., Kennedy, A. W., Belinson, J., Markman, M., and Casey, G. (1998) J. Am. Med. Assoc. 280, 719–723[Abstract/Free Full Text]
  21. Saulnier-Blache, J. S., Girard, A., Simon, M. F., Lafontan, M., and Valet, P. (2000) J. Lipid Res. 41, 1947–1951[Abstract/Free Full Text]
  22. Eichholtz, T., Jalink, K., Fahrenfort, I., and Moolenaar, W. H. (1993) Biochem. J. 291, Pt. 3, 677–680
  23. Aoki, J., Taira, A., Takanezawa, Y., Kishi, Y., Hama, K., Kishimoto, T., Mizuno, K., Saku, K., Taguchi, R., and Arai, H. (2002) J. Biol. Chem. 277, 48737–48744[Abstract/Free Full Text]
  24. Xie, Y., Gibbs, T. C., and Meier, K. E. (2002) Biochim. Biophys. Acta 1582, 270–281[Medline] [Order article via Infotrieve]
  25. Gaits, F., Fourcade, O., Le Balle, F., Gueguen, G., Gaige, B., Gassama-Diagne, A., Fauvel, J., Salles, J. P., Mauco, G., Simon, M. F., and Chap, H. (1997) FEBS Lett. 410, 54–58[CrossRef][Medline] [Order article via Infotrieve]
  26. Mauco, G., Chap, H., Simon, M. F., and Douste-Blazy, L. (1978) Biochimie (Paris) 60, 653–661
  27. Kuypers, F. A., Lewis, R. A., Hua, M., Schott, M. A., Discher, D., Ernst, J. D., and Lubin, B. H. (1996) Blood 87, 1179–1187[Abstract/Free Full Text]
  28. Rose, G., and Oaklander, M. (1965) J. Lipid Res. 6, 428–431[Abstract]
  29. Bradford, M. M. (1976) Anal. Biochem. 72, 248–254[CrossRef][Medline] [Order article via Infotrieve]
  30. Bartlett, G. R. (1959) J. Biol. Chem. 234, 466–468[Free Full Text]
  31. Bligh, E. G., and Dyer, W. J. (1959) Can. J. Biochem. Physiol. 37, 911–917
  32. Wu, G., Essex, D. W., Meloni, F. J., Takafuta, T., Fujimura, K., Konkle, B. A., and Shapiro, S. S. (1997) Blood 90, 2660–2669[Abstract/Free Full Text]
  33. Curry, F. E., Huxley, V. H., and Sarelius, I. H. (1983) in Cardiovascular Physiology: Techniques in the Life Sciences (Linden, R. T., ed) Vol. P309 (1), pp. 1–34, Elsevier, New York
  34. Michel, C. C., Mason, J. C., Curry, F. E., Tooke, J. E., and Hunter, P. J. (1974) Q. J. Exp. Physiol. Cogn. Med. Sci. 59, 283–309[Abstract/Free Full Text]
  35. Victorino, G. P., Newton, C. R., and Curran, B. (2002) J. Surg. Res. 104, 77–81[CrossRef][Medline] [Order article via Infotrieve]
  36. Bittman, R., Swords, B., Liliom, K., and Tigyi, G. (1996) J. Lipid Res. 37, 391–398[Abstract]
  37. Liliom, K., Bittman, R., Swords, B., and Tigyi, G. (1996) Mol. Pharmacol. 50, 616–623[Abstract]
  38. Sugiura, T., Tokumura, A., Gregory, L., Nouchi, T., Weintraub, S. T., and Hanahan, D. J. (1994) Arch. Biochem. Biophys. 311, 358–368[CrossRef][Medline] [Order article via Infotrieve]
  39. Tyurina, Y., Serinkan, F., Tyurin, V., Kini, V., Yalowich, J., Schroit, A. J., Fadeel, B., and Kagan, V. E. (2004) J. Biol. Chem. 279, 6056–6064[Abstract/Free Full Text]
  40. Fadok, V., Bratton, D., and Henson, P. (2001) J. Clin. Investig. 108, 957–962[CrossRef][Medline] [Order article via Infotrieve]
  41. Kim, D. K., Fukuda, T., Thompson, B. T., Cockrill, B., Hales, C., and Bonventre, J. V. (1995) Am. J. Physiol. 269, Pt. 1, L109–L118
  42. Romaschin, A. D., DeMajo, W. C., Winton, T., D'Costa, M., Chang, G., Rubin, B., Gamliel, Z., and Walker, P. M. (1992) Clin. Biochem. 25, 55–60[CrossRef][Medline] [Order article via Infotrieve]
  43. Touqui, L., and Arbibe, L. (1999) Mol. Med. Today 5, 244–249[CrossRef][Medline] [Order article via Infotrieve]
  44. de Jong, K., Larkin, S. K., Styles, L. A., Bookchin, R. M., and Kuypers, F. A. (2001) Blood 98, 860–867[Abstract/Free Full Text]
  45. Puneet, P., Moochhala, S., and Bhatia, M. (2005) Am. J. Physiol. 288, L3-L15
  46. Ware, L. B., and Matthay, M. A. (2000) N. Engl. J. Med. 342, 1334–1349[Free Full Text]
  47. Jalink, K., van Corven, E. J., and Moolenaar, W. H. (1990) J. Biol. Chem. 265, 12232–12239[Abstract/Free Full Text]
  48. Bursten, S. L., Federighi, D. A., Parsons, P., Harris, W. E., Abraham, E., Moore, E. E., Jr., Moore, F. A., Bianco, J. A., Singer, J. W., and Repine, J. E. (1996) Crit. Care Med. 24, 1129–1136[CrossRef][Medline] [Order article via Infotrieve]
  49. Niewoehner, D. E., Rice, K., Duane, P., Sinha, A. A., Gebhard, R., and Wangensteen, D. (1989) J. Appl. Physiol. 66, 261–267[Abstract/Free Full Text]
  50. Quinlan, G. J., Lamb, N. J., Evans, T. W., and Gutteridge, J. M. (1996) Crit. Care Med. 24, 241–246[CrossRef][Medline] [Order article via Infotrieve]
  51. van Nieuw Amerongen, G. P., Vermeer, M. A., and van Hinsbergh, V. W. (2000) Arterioscler. Thromb. Vasc. Biol. 20, E127–133
  52. Siess, W., Zangl, K. J., Essler, M., Bauer, M., Brandl, R., Corrinth, C., Bittman, R., Tigyi, G., and Aepfelbacher, M. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 6931–6936[Abstract/Free Full Text]
  53. Hooks, S. B., Ragan, S. P., Hopper, D. W., Honemann, C. W., Durieux, M. E., Macdonald, T. L., and Lynch, K. R. (1998) Mol. Pharmacol. 53, 188–194[Abstract/Free Full Text]
  54. Lynch, K. R., and Macdonald, T. L. (2002) Biochim. Biophys. Acta 1582, 289–294[Medline] [Order article via Infotrieve]
  55. van Corven, E. J., van Rijswijk, A., Jalink, K., van der Bend, R. L., van Blitterswijk, W. J., and Moolenaar, W. H. (1992) Biochem. J. 281, Pt. 1, 163–169
  56. He, P., Zeng, M., and Curry, F. E. (2000) Am. J. Physiol. 278, H1124–H1133

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 ASH Education BookHome page
C. R. Morris
Mechanisms of Vasculopathy in Sickle Cell Disease and Thalassemia
Hematology, January 1, 2008; 2008(1): 177 - 185.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
R. Sluyter, A. N. Shemon, W. E. Hughes, R. O. Stevenson, J. G. Georgiou, G. D. Eslick, R. M. Taylor, and J. S. Wiley
Canine erythrocytes express the P2X7 receptor: greatly increased function compared with human erythrocytes
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R2090 - R2098.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
F. A. Kuypers
Membrane Lipid Alterations in Hemoglobinopathies
Hematology, January 1, 2007; 2007(1): 68 - 73.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/2/775    most recent
M505790200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neidlinger, N. A.
Right arrow Articles by Kuypers, F. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neidlinger, N. A.
Right arrow Articles by Kuypers, F. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement